We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




A Common Nutritional Supplement Increases Fertility Rates

By HospiMedica International staff writers
Posted on 21 Jul 2010
An antiaging drug, sold over-the-counter (OTC) worldwide, improves in vitro fertilization (IVF) treatment outcome in poor responders, according to a new study. More...


Researchers at Shaare Zedek Medical Center (Jerusalem, Israel) conducted a prospective, self-controlled study of 43 women aged 26 to 44 undergoing IVF treatment. The women identified as poor responders (less than 4 oocytes retrieved) were treated with at least three months of 5-Dehydroepiandrosterone (DHEA) supplementation (75 mg/day). Biochemical parameters recorded before and after DHEA supplementation included serum-cycle day 3 Follicle Stimulating Hormone (FSH), Anti-Müllerian hormone (AMH), Inhibin B, E2, and DHEA. Ultrasound parameters recorded included antral follicle count (AFC) and endometrial thickness. To assess markers for ovarian function at different stages of follicular maturation, very early AMH, early inhibin B, AFC, and the number and quality of oocytes both before and after DHEA supplementation were recorded.

The results showed that following DHEA supplementation, there was a significant increase in antral follicle count, while no significant changes in baseline biochemical parameters were noted. The change in response to IVF treatment was also significant, with an increased peak E2 concentration, the number of follicles over 15 mm on the day of human chorionic gonadotrophin (hCG) administration, and the number of oocyte retrieved, with consequent increase in the number of metaphase II oocytes and the number of embryos. There were 11 clinical pregnancies after DHEA treatment. The study was presented at the 2010 annual conference of AYALA, the Israeli Fertility Association, held during May 2010 in Tel Aviv (Israel).

"DHEA appears to improve IVF treatment outcome, with an increase in the number of oocyte and embryos, and appreciable pregnancy rate,” concluded lead author Jordana Hyman, M.D., director of the Shaare Tzedek IVF clinic, and colleagues. "It seems that the mechanism does not include recruitment of more preantral or very small antral follicles, but rather rescue from atresia of small antral follicles (increased AFC).”

DHEA is an endogenous steroid that has been implicated in a broad range of biological effects in humans and other mammals. DHEA is produced by the adrenal glands, gonads, and the brain. It acts on the androgen receptor both directly and through its metabolites, which include androstenediol and androstenedione, which can undergo further conversion to produce the androgen testosterone and the estrogens estrone and estradiol.

Related Links:

Shaare Zedek Medical Center



Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Open Stapler
PROXIMATE Linear Cutter
IV Therapy Cart
Avalo I.V Therapy Cart
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The fiber in the brain implant is less than half a millimeter thick (Photo courtesy of Peter Aagaard Brixen)

Brain Implant Records Neural Signals and Delivers Precise Medication

Neurological diseases such as epilepsy involve complex interactions across multiple layers of the brain, yet current implants can typically stimulate or record activity from only a single point.... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.